Allergan play gooses Revance

Traders apparently believe the potential acquisition of Allergan by Valeant and Pershing Square bodes well for Revance Therapeutics (RVNC). Shares are up 20% premarket on mediocre volume.

After yesterday's close, the company announced positive results from it Phase 1/2 clinical trial for RT002 injectable botulinum toxin type A for the treatment of moderate to severe glabellar (frown) lines. Its patented TransMTS technology is designed to provide a longer duration of effect.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs